News
Featured
On May 17, the World Health Organization (WHO) released its updated Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens, the WHO included rifampicin-resistant Mycobacterium tuberculosis (RR-TB)...
News
17 Jun 2020
On March 25th, Qurient announced the results of their Phase 2 Clinical Trial (ClinicalTrials.gov number, NCT03563599 ), which was a prospective, randomized, open-label trial for proof of concept in humans of their novel anti-tuberculosis drug, Telacebec (Q203). The trial involved 61 newly-diagnosed...
27 Feb 2020
ERA4TB, or European Accelerator of Tuberculosis Regime, is a public-private initiative devoted to accelerate the development of new treatmen regimens for Tuberculosis. This project integrates more than thirty organizations from the European Union and the United States among which are the main...
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...
5 Jun 2019
**Update: The US FDA Antimicrobial Drug Advisory Committee voted in favor of the NDA 14 to 4 on June 6th, 2019** The United States Food & Drug Administration (FDA) will host the Antimicrobial Drug Advisory Committee on Thursday, June 6th to discuss the new drug application (NDA) involving new...
21 Mar 2019
On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials. It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB , followed by a question and answer session. The...
12 Mar 2019
On March 8th, TB Alliance announced its novel compound, Pretomanid, is currently being reviewed by the FDA for use against Tuberculosis. TB Alliance's press release can be found below: NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug...
29 Nov 2018
On December 6, 2018, at 7AM EST, TREAT TB will host a capacity building webinar on community engagement in MDR-TB clinical trials. It will feature a presentation from Ezio Tavora dos Santos Filho, STREAM Community Engagement Coordinator from REDE-TB , followed by a question and answer session. The...
2 Oct 2018
The first ever U.N. General Assembly’s high-level meeting (UNHLM) on tuberculosis took place on Wednesday, September 26 in New York City. The U.N. delegation of countries agreed to ambitious targets including a commitment to finding 40 million undiagnosed cases of TB by the end of 2022 and...
18 Sep 2018
In an article written by Lucica Ditiu, Executive Director, Stop TB Partnership, and Jacqueline Huh, Head, Strategic Initiatives & Innovative Financing, Stop TB, the 'valleys of death' that hold back TB new tools innovation are discussed. These two valleys occur between new tool development and...
26 Jun 2018
As the global TB drug development community pushes forward to find new drug candidates and develop novel regimens to combat the TB epidemic, we'd like to highlight some updates in the field, WGND activities, and upcoming events in 2018. An Interactive Civil Society Hearing was held on June 4th in...
21 May 2018
Bloomberg News reported this week on how world leaders can be successful in ending TB by 2030 and the demographics that TB affects most. One article discusses multi-drug and extensive drug resistant patients as well as challenges, funding needs, and the needs for new tools to defeat TB. The other...
17 Apr 2018
A new laborartory resource handbook was published in March 2018 to support TB clinical trials. The authors and summary of the handbook are below. Please click here for a link to the full handbook. Authors Kathleen Eisenach, University of Arkansas for Medical Sciences, USA Anne-Marie Demers, Desmond...
16 Nov 2017
Ending Tuberculosis Starts in Moscow (Op-ed) A meeting of the world’s health ministers in Moscow this week could prove to be a pivotal moment on the road to ending tuberculosis Nov 16, 2017 By José Luis Castro and Michel Kazatchkine A meeting of the world’s health ministers in Moscow this week...
